Cargando…
Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies
BACKGROUND: Croton membranaceus (CM) is used for benign prostate hyperplasia treatment. OBJECTIVE: Sub-chronic toxicity studies are non-existent and provided the basis for this study. MATERIALS AND METHODS: 90 days oral administration of a low dose (LD) (30 mg/kg b. wt.), medium dose (MD) (150 mg/kg...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579014/ https://www.ncbi.nlm.nih.gov/pubmed/23598919 http://dx.doi.org/10.4103/0974-8490.105640 |
_version_ | 1782260070090801152 |
---|---|
author | Afriyie, Dan K. Asare, George A. Bugyei, Kwasi Asiedu-Gyekye, Isaac Gyan, Ben A. Adjei, Samuel Addo, Phyllis Sittie, Archibald Nyarko, Alexander K. |
author_facet | Afriyie, Dan K. Asare, George A. Bugyei, Kwasi Asiedu-Gyekye, Isaac Gyan, Ben A. Adjei, Samuel Addo, Phyllis Sittie, Archibald Nyarko, Alexander K. |
author_sort | Afriyie, Dan K. |
collection | PubMed |
description | BACKGROUND: Croton membranaceus (CM) is used for benign prostate hyperplasia treatment. OBJECTIVE: Sub-chronic toxicity studies are non-existent and provided the basis for this study. MATERIALS AND METHODS: 90 days oral administration of a low dose (LD) (30 mg/kg b. wt.), medium dose (MD) (150 mg/kg b. wt.), and high dose (HD) (300 mg/kg b. wt.) CM aqueous root extract to 3 groups (n=6 each) of male Sprague-Dawley rats, alongside a control group, was undertaken. Urinalysis, hepato-renal function tests, lipid profile, cardiac enzymes, and routine hematology tests were performed. RESULTS: Triglyceride levels (C=1.05±0.19, LD=0.64±0.08, MD=0.55±0.04, HD=0.50±0.02 mmol/L) were significantly reduced (P<0.05). Very low density lipoprotein (C=0.48±0.09, LD=0.29±0.04, MD=0.25±0.02, HD=0.23±0.01 mmol/L) decreased significantly (P<0.05). Cardiac enzymes-creatinine kinase (C=568±172, LD=315±79, MD=441±209, HD=286±81 IU/L) decreased markedly (P<0.05) alongside lactate dehydrogenase (C=2675±875, LD=1667±1229, MD=1186±442, HD=855±239 IU/L) (P<0.05). CONCLUSION: C. membranaceus aqueous root extract is non-toxic but demonstrates anti-atherogenic and anti-ischemic potentials. |
format | Online Article Text |
id | pubmed-3579014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-35790142013-02-28 Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies Afriyie, Dan K. Asare, George A. Bugyei, Kwasi Asiedu-Gyekye, Isaac Gyan, Ben A. Adjei, Samuel Addo, Phyllis Sittie, Archibald Nyarko, Alexander K. Pharmacognosy Res Original Article BACKGROUND: Croton membranaceus (CM) is used for benign prostate hyperplasia treatment. OBJECTIVE: Sub-chronic toxicity studies are non-existent and provided the basis for this study. MATERIALS AND METHODS: 90 days oral administration of a low dose (LD) (30 mg/kg b. wt.), medium dose (MD) (150 mg/kg b. wt.), and high dose (HD) (300 mg/kg b. wt.) CM aqueous root extract to 3 groups (n=6 each) of male Sprague-Dawley rats, alongside a control group, was undertaken. Urinalysis, hepato-renal function tests, lipid profile, cardiac enzymes, and routine hematology tests were performed. RESULTS: Triglyceride levels (C=1.05±0.19, LD=0.64±0.08, MD=0.55±0.04, HD=0.50±0.02 mmol/L) were significantly reduced (P<0.05). Very low density lipoprotein (C=0.48±0.09, LD=0.29±0.04, MD=0.25±0.02, HD=0.23±0.01 mmol/L) decreased significantly (P<0.05). Cardiac enzymes-creatinine kinase (C=568±172, LD=315±79, MD=441±209, HD=286±81 IU/L) decreased markedly (P<0.05) alongside lactate dehydrogenase (C=2675±875, LD=1667±1229, MD=1186±442, HD=855±239 IU/L) (P<0.05). CONCLUSION: C. membranaceus aqueous root extract is non-toxic but demonstrates anti-atherogenic and anti-ischemic potentials. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3579014/ /pubmed/23598919 http://dx.doi.org/10.4103/0974-8490.105640 Text en Copyright: © Pharmacognosy Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Afriyie, Dan K. Asare, George A. Bugyei, Kwasi Asiedu-Gyekye, Isaac Gyan, Ben A. Adjei, Samuel Addo, Phyllis Sittie, Archibald Nyarko, Alexander K. Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies |
title | Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies |
title_full | Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies |
title_fullStr | Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies |
title_full_unstemmed | Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies |
title_short | Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies |
title_sort | anti-atherogenic and anti-ischemic potentials of croton membranaceus observed during sub-chronic toxicity studies |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579014/ https://www.ncbi.nlm.nih.gov/pubmed/23598919 http://dx.doi.org/10.4103/0974-8490.105640 |
work_keys_str_mv | AT afriyiedank antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies AT asaregeorgea antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies AT bugyeikwasi antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies AT asiedugyekyeisaac antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies AT gyanbena antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies AT adjeisamuel antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies AT addophyllis antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies AT sittiearchibald antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies AT nyarkoalexanderk antiatherogenicandantiischemicpotentialsofcrotonmembranaceusobservedduringsubchronictoxicitystudies |